Adverse Event Reporting for Medications and Vaccines Before and During the COVID-19 Pandemic: An Observational and Retrospective Study
DOI:
https://doi.org/10.30968/jhphs.2025.162.1260Abstract
Objective: Compare the profile of suspected adverse events (AE) reports associated with medicines and vaccines before and during the COVID-19 pandemic. Method: An observational, retrospective study was conducted using data extracted from the VigiMed database. Spreadsheets were reviewed and processed, starting with the exclusion of the lines that had incomplete and uninterpretable data on the following variations related to the patient, related to the AE, related to the medication/vaccine and related to the notifier. Following database extract, reports were categorized into two groups: Group 1 (G1), before the pandemic; and Group 2 (G2), during the pandemic. Categorical variables were compared using absolute and relative frequency. Results: There was no difference between the notification profiles in the two groups about the sex and age of the individuals affected by AE related to medicines and vaccines. The notifiers in G1 were predominantly pharmacists (77.5%) while in G2, it was the consumers (55.9%). With respect to the products that were the target of the notifications, in G1 the most prevalent classes were analgesics, antibiotics and antineoplastics. In G2, there were vaccines against COVID-19 and immunosuppressants. About reports of suspected fatal AE related to medicines and vaccines, the most prevalent products in G1 were antimicrobials and antiepileptics, while G2 included antineoplastics, COVID-19 vaccines and immunosuppressants. Conclusion: The comparative of AE to drugs and vaccines notifications revealed that the COVID-19 pandemic contributed to a change in the profile of the notifiers, as well as in the type of product targeted by the notifications most frequently reported. These findings highlight the landscape of pharmacovigilance during public health emergencies.
Downloads
References
Alhawassi TM, Krass I, Bajorek BV, et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079-2086. doi:10.2147/CIA.S71178
Anacleto TA, Perini E, Rosa MB, et al. Medication errors and drug-dispensing systems in a hospital pharmacy. Clinics (Sao Paulo). 2005;60(4):325-332. doi:10.1590/s1807-59322005000400011
Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16(5):481-485. doi:10.7861/clinmedicine.16-5-481
Zanetti ACB, Dias BM, Bernardes A, et al. Incidence and preventability of adverse events in adult patients admitted to a Brazilian teaching hospital. PLoS One. 2021;16(4):e0249531. doi:10.1371/journal.pone.0249531
Bos JM, Kalkman GA, Groenewoud H, et al. Prediction of clinically relevant adverse drug events in surgical patients. PLoS One. 2018;13(8):e0201645. doi:10.1371/journal.pone.0201645
Mota DM, Vigo Á, Kuchenbecker RS. Reações adversas a medicamentos no sistema de farmacovigilância do Brasil, 2008 a 2013: estudo descritivo. Cad Saude Publica. 2019;35(8):e00148818. doi:10.1590/0102-311X00148818
ISMP. Desafio Global de Segurança do Paciente – Medicação Sem Danos. Belo Horizonte: ISMP-Brasil; 2018.
Mota DM, Vigo Á, Kuchenbecker RS. Avaliação do desempenho do Sistema Nacional de Notificações para a Vigilância Sanitária: uma ferramenta do sistema de farmacovigilância no Brasil. Cien Saude Colet. 2020;25(5):1955-1966. doi:10.1590/1413-81232020255.19522018
Vogler M, Ricci CH, Araújo FK, et al. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil. Frente. Farmacol. 2020;34(5):327–34. doi: 10.3389/fphar.2021.789872
OPAS/OMS. Segurança dos medicamentos: um guia para detectar e notificar reações adversas a medicamentos. Porque os profissionais de saúde precisam entrar em ação. Brasília: OMS;2005
Melo JRR, Duarte EC, Moraes MV, Fleck K, Arrais PSD. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cad Saude Publica. 2021;37(4):e00053221. doi:10.1590/0102-311X00053221
Ministério da Saúde. Noções em farmacovigilância. Available at: https://www.gov.br/anvisa/pt-br/acessoainformacao/dadosabertos/informacoes-analiticas/notificacoes-defarmacovigilancia. Accessed: January, 9, 2023.
Fialho ICTS, Monteiro DE, Soares RDS, et al. Reações adversas relacionadas aos inibidores de checkpoint: uma revisão integrativa. Rev Enferm UERJ. 2021; 29: e58363. doi: 10.12957/reuerj.2021.58363
Lin Y, Hu Z, Zhao Q, et al. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12): e0008961. doi: 10.1371/journal.pntd.0008961
Dias P, Ribeiro CF, Marques FB. Medidas de desproporcionalidade na deteção de sinal em farmacovigilância. Rev Port Farmacoter. 2014;6(1):31–5. doi: 10.25756/rpf.v6i1.36
Felix T, Jordan JB, Akers C, et al. Current state of biologic pharmacovigilance in the European Union: improvements are needed. Expert Opin Drug Saf. 2019;18(3):231-240. doi:10.1080/14740338.2019.1577818
Duarte M, Ferreira P, Soares M, et al. Community pharmacists’ attitudes towards adverse drug reaction reporting and their knowledge of the new pharmacovigilance legislation in the southern region of Portugal: a mixed methods study. Drugs Ther Perspect. 2015; 31 (9): 316–22. doi: 10.1007/s40267-015-0227-8
Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B. Frequent Adverse Drug Reactions, and Medication Groups under Suspicion. Dtsch Arztebl Int. 2018;115(23):393-400. doi:10.3238/arztebl.2018.0393
Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1
Montano D. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Front Public Health. 2022;9:756633. doi:10.3389/fpubh.2021.756633
Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-982. doi:10.15585/mmwr.mm7027e2
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-636. doi:10.1038/s41577-021-00592-1
Iftikhar S, Sarwar MR, Saqib A, Sarfraz M. Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan. PLoS One. 2018;13(6):e0199456. doi:10.1371/journal.pone.0199456
Montastruc JL, Lafaurie M, de Canecaude C, et al. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2021;87(11):4334-4340. doi:10.1111/bcp.14851
Jo HG, Jeong K, Ryu JY, et al. Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database. J Pers Med. 2021;12(1):5. doi:10.3390/jpm12010005
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to JHPHS : (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to JHPHS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
